A multidisciplinary evaluation of the effectiveness of cyclosporine a in dystrophic mdx mice
Related Experiment Video
Updated: Aug 19, 2026
Assessing Functional Performance in the Mdx Mouse Model
Published on: March 27, 2014
Annamaria De Luca1, Beatrice Nico, Antonella Liantonio
1Sezione di Farmacologia, Dipartimento Farmacobiologico, Facoltà di Farmacia, Università degli Studi di Bari, Via Orabona 4, Campus, 70125 Bari, Italy. adeluca@farmbiol.uniba.it
Abstract:
Chronic inflammation is a secondary reaction of Duchenne muscular dystrophy and may contribute to disease progression. To examine whether immunosuppressant therapies could benefit dystrophic patients, we analyzed the effects of cyclosporine A (CsA) on a dystrophic mouse model. Mdx mice were treated with 10 mg/kg of CsA for 4 to 8 weeks throughout a period of exercise on treadmill, a protocol that worsens the dystrophic condition. The CsA treatment fully prevented the 60% drop of forelimb strength induced by exercise. A significant amelioration (P < 0.05) was observed in histological profile of CsA-treated gastrocnemius muscle with reductions of nonmuscle area (20%), centronucleated fibers (12%), and degenerating area (50%) compared to untreated exercised mdx mice. Consequently, the percentage of normal fibers increased from 26 to 35% in CsA-treated mice. Decreases in creatine kinase and markers of fibrosis were also observed. By electrophysiological recordings ex vivo, we found that CsA counteracted the decrease in chloride conductance (gCl), a functional index of degeneration in diaphragm and extensor digitorum longus muscle fibers. However, electrophysiology and fura-2 calcium imaging did not show any amelioration of calcium homeostasis in extensor digitorum longus muscle fibers. No significant effect was observed on utrophin levels in diaphragm muscle. Our data show that the CsA treatment significantly normalized many functional, histological, and biochemical endpoints by acting on events that are independent or downstream of calcium homeostasis. The beneficial effect of CsA may involve different targets, reinforcing the usefulness of immunosuppressant drugs in muscular dystrophy.
Insights
Cyclosporine A (CsA) treatment improved muscle strength and reduced degeneration in a mouse model of Duchenne muscular dystrophy. This immunosuppressant therapy offers potential benefits for muscular dystrophy patients.
Area of Science:
- Immunology
- Neurology
- Muscle Biology
Background:
- Duchenne muscular dystrophy (DMD) involves chronic inflammation, contributing to disease progression.
- Immunosuppressant therapies are being investigated for potential benefits in DMD patients.
Purpose of the Study:
- To evaluate the efficacy of cyclosporine A (CsA) in a mouse model of Duchenne muscular dystrophy (mdx mice).
- To assess CsA's impact on muscle function, histology, and biochemical markers under exercise stress.
Main Methods:
- Mdx mice were treated with CsA (10 mg/kg) for 4-8 weeks during treadmill exercise.
- Muscle strength, histological profiles (gastrocnemius), creatine kinase, fibrosis markers, and electrophysiological properties were analyzed.
Main Results:
- CsA treatment fully prevented exercise-induced forelimb strength loss.
- Histological improvements included reduced nonmuscle area, centronucleated fibers, and degenerating areas in gastrocnemius muscle.
- CsA counteracted decreased chloride conductance in diaphragm and extensor digitorum longus muscle fibers, indicating reduced degeneration.
Conclusions:
- Cyclosporine A demonstrates significant benefits in functional, histological, and biochemical aspects of muscular dystrophy in mdx mice.
- CsA's positive effects appear independent of calcium homeostasis, suggesting multifaceted therapeutic targets.
- Immunosuppressant drugs like CsA show promise for treating muscular dystrophy.
